相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
Fadia Attia et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2020)
Structures of human ENT1 in complex with adenosine reuptake inhibitors
Nicholas J. Wright et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2019)
Chemoresistance in Pancreatic Cancer
Siyuan Zeng et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer
Takehito Yamamoto et al.
ASIAN JOURNAL OF SURGERY (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Challenges in diagnosis of pancreatic cancer
Lulu Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Emerging Roles of Nucleoside Transporters
Marcal Pastor-Anglada et al.
FRONTIERS IN PHARMACOLOGY (2018)
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics
Divya Murthy et al.
FRONTIERS IN PHYSIOLOGY (2018)
Inward- and outward-facing homology modeling of human concentrative nucleoside transporter 3 (hCNT3) predicts an elevator-type transport mechanism
Sylvia Y. M. Yao et al.
CHANNELS (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
Jaihwan Kim et al.
PLOS ONE (2018)
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
Andrew McGuigan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Chemoresistance and the Self-Maintaining Tumor Microenvironment
Gulcen Yeldag et al.
CANCERS (2018)
MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma
Shailendra K. Gautam et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Differential expression of hENT1 and hENT2 in colon cancer cell lines
Y. Liu et al.
GENETICS AND MOLECULAR RESEARCH (2017)
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
Patricia Dauer et al.
PANCREATOLOGY (2017)
The molecular mechanisms of chemoresistance in cancers
Hua-Chuan Zheng
ONCOTARGET (2017)
Pancreatic Cancer Chemoresistance to Gemcitabine
Manoj Amrutkar et al.
CANCERS (2017)
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
Bruno Vincenzi et al.
BRITISH JOURNAL OF CANCER (2017)
Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer
Adrian Stecula et al.
BIOCHEMISTRY (2017)
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer
Surendra K. Shukla et al.
CANCER CELL (2017)
Functional reconstitution of human equilibrative nucleoside transporter-1 into styrene maleic acid co-polymer lipid particles
Shahid Rehan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2017)
Current and Emerging Therapies in Metastatic Pancreatic Cancer
Gulam Abbas Manji et al.
CLINICAL CANCER RESEARCH (2017)
Anti-cancer effect of Annona Muricata Linn Leaves Crude Extract (AMCE) on breast cancer cell line
Syed Umar Faruq Syed Najmuddin et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2016)
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3
Rachel A. Hesler et al.
CARCINOGENESIS (2016)
Current standards and new innovative approaches for treatment of pancreatic cancer
Thierry Conroy et al.
EUROPEAN JOURNAL OF CANCER (2016)
Targeting EGF-receptor(s)-STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer
Parthasarathy Seshacharyulu et al.
ONCOTARGET (2015)
Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets
Marcal Pastor-Anglada et al.
FRONTIERS IN PHARMACOLOGY (2015)
miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer
F. Lahdaoui et al.
ONCOGENE (2015)
Mucins and tumor resistance to chemotherapeutic drugs
Nicolas Jonckheere et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer
Anupama Mittal et al.
BIOMATERIALS (2014)
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
Lucas de Sousa Cavalcante et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
ynthesis, characterization, and evaluation of poly (D, L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy
Sumit Arora et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2014)
Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer
Fangfeng Liu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4)
Chunmei Wang et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling
Muzafar A. Macha et al.
CANCER LETTERS (2013)
Current concepts and novel targets in advanced pancreatic cancer
Patrick Michl et al.
GUT (2013)
Mucins in pancreatic cancer and its microenvironment
Sukhwinder Kaur et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family
N. Skrypek et al.
ONCOGENE (2013)
Human Concentrative Nucleoside Transporter 3 Transfection with Ultrasound and Microbubbles in Nucleoside Transport Deficient HEK293 Cells Greatly Increases Gemcitabine Uptake
Robert J. Paproski et al.
PLOS ONE (2013)
Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner
S. Perez-Torras et al.
CELL DEATH & DISEASE (2013)
Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket
Pedro Cano-Soldado et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
Thymoquinone: Potential cure for inflammatory disorders and cancer
Chern Chiuh Woo et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism
Maria P. Torres et al.
CANCER LETTERS (2012)
Mucin-based Targeted Pancreatic Cancer Therapy
Maria P. Torres et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
The role of transporters in the toxicity of nucleoside and nucleotide analogs
Christopher A. Koczor et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
Raphael Marechal et al.
GASTROENTEROLOGY (2012)
A Mild Form of SLC29A3 Disorder: A Frameshift Deletion Leads to the Paradoxical Translation of an Otherwise Noncoding mRNA Splice Variant
Alexandre Bolze et al.
PLOS ONE (2012)
MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells
Sanjeev K. Srivastava et al.
CARCINOGENESIS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3′-deoxy-3′-fluorothymidine
Robert J. Paproski et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells
Wolfgang Hagmann et al.
NEOPLASIA (2010)
Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
Jennifer L. Spratlin et al.
Cancers (2010)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Y. Nakano et al.
BRITISH JOURNAL OF CANCER (2007)
Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2
RP Owen et al.
DRUG METABOLISM AND DISPOSITION (2006)
Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)
MWL Ritzel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
